Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences (NYSE:RCUS) announced inducement equity awards for two new employees on March 9, 2026. The Compensation Committee granted options to purchase 17,050 shares at an exercise price of $23.43 per share and 8,550 restricted stock units under the company’s 2020 Inducement Plan. The awards used the NYSE "inducement exception" (Rule 303A.08) and reflect hiring-related equity compensation for clinical-stage operations.
Arcus Biosciences (NYSE:RCUS) said its management team will participate in two investor conferences in Miami in March 2026: the Leerink Global Healthcare Conference on March 9 (fireside chat & 1x1s) and the Barclays 28th Annual Global Healthcare Conference on March 10 (1x1s).
A live webcast of the March 9 fireside chat will be available via the company’s Investors & Media website, with a replay posted after the event.
Arcus Biosciences (NYSE:RCUS) reported Q4 and full-year 2025 results and a pipeline update highlighting clinical progress for casdatifan and balance sheet strength. Casdatifan 100mg QD showed median PFS of 15.1 months and confirmed ORR of 45.2% (DCO Jan 30, 2026).
PEAK-1 Phase 3 is enrolling; a 1L registrational Phase 3 is planned by end-2026. Cash totaled $1.0 billion at year-end, supporting runway into at least H2 2028. Quemliclustat Phase 3 enrollment completed; results expected H1 2027.
Arcus Biosciences (NYSE:RCUS) reported updated ARC-20 results for casdatifan in late-line metastatic clear cell RCC. The 100mg QD tablet cohort showed mPFS 15.1 months and cORR 45% (DCO Jan 30, 2026). Pooled mPFS was 12.2 months with cORR 35%. Biomarker analysis linked sustained sEPO suppression to clinical benefit. No unexpected safety signals were observed; anemia-related discontinuations were 0% and hypoxia discontinuations were 3%.
Arcus Biosciences (NYSE:RCUS) will host a conference call and webcast on Feb 25, 2026 at 1:30 PM PT / 4:30 PM ET to discuss fourth-quarter and full-year 2025 financial results and a pipeline update.
Investors can join by phone (Access Code: 190500), register online, or view a live webcast and slide presentation on the company website; a replay will be available after the event.
Arcus Biosciences (NYSE:RCUS) announced inducement equity awards for three new employees under its 2020 Inducement Plan. The Compensation Committee granted options to purchase a total of 16,650 shares at an exercise price of $22.13 per share (the closing price on January 23, 2026) and 8,400 restricted stock units to acquire common stock.
The grants were made pursuant to the company’s 2020 Inducement Plan, approved by the board in January 2020 under the NYSE inducement exception (Rule 303A.08).
Arcus (NYSE:RCUS) outlined 2026 priorities focused on advancing casdatifan (HIF-2a inhibitor) across late-line and first-line ccRCC, with at least three casdatifan data presentations planned in 2026 and a targeted Phase 3 1L study initiation by year-end 2026. The company expects to start a first oral MRGPRX2 antagonist clinical program in 2026 and advance a small-molecule TNF inhibitor into the clinic in late 2026/early 2027. Arcus reports approximately $1 billion cash and investments and expects funding through at least the second half of 2028, assuming a rapid wind down of select studies. Arcus will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Arcus Biosciences (NYSE:RCUS) announced that CEO Terry Rosen, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Wednesday, January 14, 2026 at 3:00 pm PT. A live webcast will be available via the company’s Investors & Media website and a replay will be posted after the event.
Arcus (NYSE:RCUS) will discontinue the Phase 3 STAR-221 study evaluating domvanalimab-based combination in advanced gastric and esophageal cancers after an Independent Data Monitoring Committee determined the trial met futility at a pre-specified interim overall survival analysis.
Arcus will stop STAR-221 and the Phase 2 EDGE-Gastric study, continue patient transition planning, and redirect R&D resources toward casdatifan (HIF-2a inhibitor) and an emerging inflammation & immunology small-molecule portfolio. Arcus reported casdatifan showed robust single-agent activity in >120 patients with late-line ccRCC and plans multiple casdatifan readouts and initiations across 2026, with potential Phase 3 registrational starts in late 2026. Arcus has ~$1B cash and investments, which it expects will fund operations into at least H2 2028.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted equity inducement awards on December 9, 2025. The grants include stock options to purchase 3,600 shares at an exercise price of $25.80 (the December 8, 2025 closing price) and 1,800 restricted stock units. The awards were made under the company's 2020 Inducement Plan pursuant to the NYSE inducement exception (Rule 303A.08) and were approved by the board in January 2020.